Astex Forms Alliance With J&J's Janssen | Chemical & Engineering News
Volume 86 Issue 24 | p. 33 | Concentrates
Issue Date: June 16, 2008

Astex Forms Alliance With J&J's Janssen

Department: Business | Collection: Sustainability

Astex Therapeutics will work with Janssen Pharmaceutica, a Johnson & Johnson company in Belgium, to develop anticancer drugs. In exchange for $37 million in upfront fees, research funding, and an equity investment in Astex, Janssen gets an exclusive license to compounds from the British firm's fibroblast growth factor receptor (FGFR) inhibitor program. Astex has discovered selective FGFR inhibitors using its fragment-based drug discovery platform. Astex could receive $500 million or more, excluding royalties, in milestone payments.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment